Related Experiment Video

Updated: Jun 24, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?

Stephanie L Nott1, Yanfang Huang, Brian R Fluharty

  • 1Department of Biochemistry & Biophysics, University of Rochester Medical School, Rochester, NY, 14642, USA.

Current Pharmacogenomics and Personalized Medicine
|April 2, 2009
PubMed

Insights

Estrogen receptors (ER) alpha and beta regulate tissue functions and cancer development. ERbeta gene variations may influence how patients respond to estrogen-targeting cancer therapies, impacting treatment efficacy.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Estrogen hormones critically regulate tissue functions, primarily through estrogen receptors (ER) alpha and beta.
  • Estrogen receptors are transcription factors controlling cellular growth, differentiation, and death, and are implicated in target tissue malignancies.
  • Current treatments for estrogen-dependent cancers involve agents that interfere with ER function, but treatment efficacy varies.

Purpose of the Study:

  • To review recent findings on estrogen receptor beta (ERbeta) polymorphisms.
  • To provide a functional perspective on ERbeta polymorphisms and their potential pharmacogenomic implications in cancer treatment.

Main Methods:

  • Literature review of recent studies on ERbeta gene polymorphisms.
  • Analysis of functional data linking ERbeta variants to estrogenic signaling and drug response.

Main Results:

  • Estrogen receptor alpha (ERalpha) polymorphisms are known contributors to differential responses to estrogen competitors.
  • Emerging evidence suggests ERbeta polymorphisms also play a role in variable treatment outcomes.
  • Understanding ERbeta variants offers insights into personalized medicine approaches.

Conclusions:

  • Polymorphisms in estrogen receptor beta (ERbeta) are increasingly recognized as significant factors in therapeutic response.
  • Pharmacogenomic insights from ERbeta variations can guide the development of more effective, individualized cancer treatments.
  • Further research into ERbeta polymorphisms is crucial for optimizing estrogen-dependent malignancy therapies.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...